HR negative

This synthesis underscores the need for pathway-level, microenvironment-informed, and population-representative approaches to DCIS risk stratification. Advancing such frameworks will be essential for identifying actionable biomarkers, refining early intervention strategies, and ultimately reducing racial disparities in breast cancer outcomes.

Durvalumab plus T-DXd demonstrated clinically relevant efficacy for first-line treatment of metastatic HR-negative, HER2-low breast cancer, with no unexpected toxicities observed. ClinicalTrials.gov identifier: NCT03742102 .

Methods We derived a novel PDX from a patient with hormone receptor negative, HER2-positive IBC refractory to neoadjuvant chemotherapy with Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP)...We performed short-tandem repeat (STR) profiling, plotted tumor growth curves for mice treated with alpelisib/everolimus vs. untreated, and immunohistochemistry (IHC), and performed clinical genomic assays...Conclusion We established a PDX of a HER2-positive IBC tumor with a PIK3CA hotspot mutation (H1047R) refractory to TCHP. Targeting the PI3K/mTOR pathway may be useful to overcome resistance in HER2-positive IBC with a H1047R mutation in PIK3CA.

Our study highlights pDCs and IFN signaling as hallmarks of effective anti-tumor immunity in TNBC. Immunotype-based profiling underscores the limited prognostic value of sTILs alone in immune-excluded tumors and supports pDCs and IFN pathways as potential biomarkers for prognosis and therapeutic development in TNBC.

P1/2, N=13, Terminated, Universitair Ziekenhuis Brussel | Completed --> Terminated; Delay in recruitment

In a real-world setting, anthracycline-free neoadjuvant chemotherapy with dual HER2 blockade achieved pCR rates comparable to anthracycline-containing regimens with acceptable toxicity and preserved cardiac safety, suggesting that it may be a reasonable treatment option for selected patients.

By targeting this aberrant let-7b-5p-mediated AR signaling pathway with AR inhibitor enzalutamide, the growth and survival of preneoplastic and preinvasive lesions were significantly reduced in cell line models. Overall, our study highlights the role of let-7b-5p-mediated aberrant AR signaling in breast tumorigenesis and as a potential target for prevention in populations at risk for hormone receptor-negative breast cancer.

Higher AR expression was associated with improved neoadjuvant treatment response in HER2-positive breast cancer, particularly in the hormone receptor-negative subgroup. However, given the retrospective single-center design and inconsistent findings in the overall population, the clinical value of AR assessment remains preliminary and requires validation in larger prospective studies.

Chemotherapy was the first-line regimen in 83 of 162 patients (51%), endocrine monotherapy in 55 of 162 (34%), and trastuzumab-pertuzumab-taxane or cyclin-dependent kinase 4 and 6 inhibitor-based regimens in eight of 162 (5%). 87534309); Center for Global Health at the United States-National Cancer Institute at the National Institutes of Health (contract award No. HHSN2612010000871/NO2-PC-2010-00087); Fogarty International Center, NIH, HHS; and Susan G. Komen for the Cure; in Argentina, Instituto Nacional del Cáncer (Ministry of Health), Fundación Argentina de Nanotecnología, Agencia Nacional de Promoción Científica y Tecnológica, CONICET (Ministry of Science, Technology, and Productive Innovation); Brazil, Ministério da Saúde (Ministry of Health); Chile, Instituto de Salud Pública (Public Health Institute) and Ministerio de Salud (Ministry of Health); and Mexico, Consejo Estatal de Ciencia y Tecnología de Jalisco (COECYTJAL) and Universidad de Sonora (University of Sonora).

In patients with HER2-positive breast cancer treated with pertuzumab-based neoadjuvant therapy, treatment response appears to be primarily influenced by clinicopathological and treatment-related factors rather than systemic inflammatory status. Peripheral blood inflammatory biomarkers derived from routine laboratory parameters showed limited value in predicting pCR in this setting.

This retrospective single-center study included 75 patients with HER2-positive invasive breast cancer treated with neoadjuvant chemotherapy plus dual anti-HER2 blockade (trastuzumab and pertuzumab). Given the modest discriminative performance and lack of external validation, these findings should be interpreted cautiously. Further validation in larger independent cohorts is required before the score can be considered for clinical stratification or implementation.

Our findings provide evidence of BRCA1 epigenetic silencing in breast tumours from African women, particularly within aggressive hormone receptor-negative subtypes. These results suggest that BRCA1 promoter methylation may represent a clinically informative biomarker for patient stratification and highlight the importance of validation in larger, population-representative cohorts before clinical translation.